Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1965 Nov;20(6):555–561. doi: 10.1136/thx.20.6.555

Cyclophosphamide in the management of advanced bronchial carcinoma.

R D McLean
PMCID: PMC1018984  PMID: 4159571

Full text

PDF
557

Images in this article

559Image
on p.559
559Image
on p.559
560Image
on p.560
560Image
on p.560

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDERS C. J., KEMP N. H. Cyclophosphamide in treatment of disseminated malignant disease. Br Med J. 1961 Dec 9;2(5266):1516–1523. doi: 10.1136/bmj.2.5266.1516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. ARNOLD H., BOURSEAUX F., BROCK N. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-ASTA) in experimental tumours of the rat. Nature. 1958 Mar 29;181(4613):931–931. doi: 10.1038/181931a0. [DOI] [PubMed] [Google Scholar]
  3. ARONOVITCH M., MEAKINS J. F., GROSZMAN M. Use of cyclophosphamide in advanced malignancies. Can Med Assoc J. 1960 Nov 5;83:997–1002. [PMC free article] [PubMed] [Google Scholar]
  4. BERGSAGEL D. E., LEVIN W. C. A prelusive clinical trial of cyclophosphamide. Cancer Chemother Rep. 1960 Jul;8:120–134. [PubMed] [Google Scholar]
  5. BROCK N., WILMANNS H. Wirkung eines zyklischen N-Lost-Phosphamidesters auf experimentall erzeugte Tumoren der Ratte; chemotherapeutische Wirksamkeit und pharmakologische Eigenschaften von B 518 ASTA. Dtsch Med Wochenschr. 1958 Mar 21;83(12):453–458. doi: 10.1055/s-0028-1114243. [DOI] [PubMed] [Google Scholar]
  6. DICK D. A., PHILLIPS A. F. Clinical experience with cyclophosphamide in malignant disease. Can Med Assoc J. 1961 Oct 28;85:974–986. [PMC free article] [PubMed] [Google Scholar]
  7. DITTRICH H. [Clinical experiences with the cytostatic drug Endoxan]. Arzneimittelforschung. 1961 Mar;11:207–210. [PubMed] [Google Scholar]
  8. ECKHARDT S., SELLEI C., HARTAI F. [Clinical experiences with endoxan]. Munch Med Wochenschr. 1959 Dec 4;101:2273–2275. [PubMed] [Google Scholar]
  9. GERHARTZ H., ALGENSTAEDT D., KESSEL I. [The principles of chemotherapy with Endoxan]. Internist (Berl) 1960 Sep;1:278–292. [PubMed] [Google Scholar]
  10. GRENVILLE-MATHERS R., TRENCHARD H. J. CYTOTOXIC DRUGS IN BRONCHIAL CARCINOMA. Lancet. 1964 Dec 5;2(7371):1200–1201. doi: 10.1016/s0140-6736(64)91040-2. [DOI] [PubMed] [Google Scholar]
  11. GROSS R., LAMBERS K. Erste Erfahrungen in der Behandlung maligner Tumoren mit einem neuen N-Lost-Phosphamidester. Dtsch Med Wochenschr. 1958 Mar 21;83(12):458–462. doi: 10.1055/s-0028-1114244. [DOI] [PubMed] [Google Scholar]
  12. HEALY J. B. CYCLOPHOSPHAMIDE IN MALIGNANT DISEASE. Lancet. 1964 Jan 11;1(7324):77–79. doi: 10.1016/s0140-6736(64)91393-5. [DOI] [PubMed] [Google Scholar]
  13. LEVINE B., WEISBERGER A. S. The response of various types of bronchogenic carcinoma to nitrogen mustard. Ann Intern Med. 1955 May;42(5):1089–1096. doi: 10.7326/0003-4819-42-5-1089. [DOI] [PubMed] [Google Scholar]
  14. PAPAC R., PETRAKIS N. L., AMINI F., WOOD D. A. Comparative clinical evaluation of two alkylating agents: mannitol mustard and cyclophosphamide (cytoxan). J Am Med Assoc. 1960 Mar 26;172:1387–1391. doi: 10.1001/jama.1960.63020130004012. [DOI] [PubMed] [Google Scholar]
  15. REEVE T. S. Treatment of malignant disease with an alkylating agent: review of 100 patients treated with "Endoxan". Med J Aust. 1961 May 13;48(1):686–689. doi: 10.5694/j.1326-5377.1961.tb69060.x. [DOI] [PubMed] [Google Scholar]
  16. WATSON W. L., BERG J. W. Oat cell lung cancer. Cancer. 1962 Jul-Aug;15:759–768. doi: 10.1002/1097-0142(196207/08)15:4<759::aid-cncr2820150410>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  17. WIELAND C., WIELAND S. [Trials in endoxan therapy]. Munch Med Wochenschr. 1961 Nov 3;103:2160–2163. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES